The OncoAlert weekly round-up is here 🥁🥁🥁🥁

Make sure to REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… ☑️☑️

What to expect this week 🤓🤓
Updates from practice-changing trials 💉💉
Several pivotal policy and prevention trials 🆕🆕

Greatly summarized by

Out in Science Magazine

Finding the missing link between☀️ and🦀

☑️Vit-D availability >⬆️ Immune activation and IO efficacy

☑️Regulation of GI microbiome by Vit-D availability>Role of B. fragilis 🦠🦠

🔎Paves the way for more IO and Vit-D studies (PROVIDENCE study)

Congrats

The OncoAlert🚨NEWSLETTER OUT
Covering May 2-8, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

✅ The Lancet Commission on #ProstateCancer
✅DESTINY-PanTumor01
✅Osimertinib+Local tx for brain🧠mets in EGFRm #NSCLC 🫁
✅ASCENT in Triple Negative

📊GLP1 Agonists in T2DM and Risk of Prostate, Kidney, and Bladder Cancers
European Urology Oncology

🚨Bladder cancer
HR 1.47 (1.06–2.04), p = 0.02
compared to SGLT2 inhibitors

🚨Kidney cancer
HR 1.45 (1.13–1.86), p = 0.003
compared to metformin

🚨Prostate cancer
HR 1.32 (1.07–1.63), p

Personal selection of 30 new (+ new-ish) ADCs that will be presented at #ASCO24 divided by payloads and targets.

Notes:
- Including 'publication only' abstracts
- Not including mainstream ADCs and/or combo
- Not including trial in progress

📢Esophageal SCC-Definitive CRT:
Capecitabin vs. XELOX vs. Cis-5FU
CRTCOESC trial
Journal of Clinical Oncology

✅2-year OS rates did not differ, capecitabine showed a lower incidence of grade ≥3 AEs
✅2 cycles of consolidation ChT provided better OS

➡️246 patients
➡️2 cycles of capecitabin or

🔈Are NECTIN4 amplifications genomic predictors of EV responses? ✅NECTIN4 amp 96% BOR
Nonamp 32% (<.001)
✅92% risk reduction for death (<.001)
⁉️Perhaps FISH might suffice without validation
ASCO ASCOPost ESMO - Eur. Oncology OncoAlert Yüksel Ürün Niklas Klümper Emre Yekedüz

DESTINY-PanTumor01
Study evaluates trastuzumab deruxtecan, in patients with metastatic solid tumors harboring specific activating HER2 🧬mutations

✅Demonstrating significant anti-tumor activity and durable responses

➡️suggesting potential for broader application across various

🔬 Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors, with a 29.4% objective response rate in heavily treated patients. Safety profile manageable, supporting further investigation across tumor types. #CancerResearch #HER2Mutations OncoAlert

Out in eClinicalMedicine – The Lancet Discovery Science

An SR-MA of psychological outcomes in rare cancers 🦓🦓

☑️Over 50.000 patients
☑️Increased depression (RR = 2.61) and anxiety (RR = 2.66)
⚠️⚠️Higher rates of suicide and PTSD
Call for immediate action ‼️‼️

Kudos to all authors Valerie Yang
#OncoAlert

Our recent study has been published in #clinicalgenitourinarycancer 🤓

📣Study shows systemic treatment prior to brain metastasis (BM) diagnosis in metastatic renal cell cancer patients significantly extends BM-free survival compared to treatment-naïve patients.

✅Emphasizes importance of treatment evaluation and active surveillance in mRCC

Want to know more about the ADCs in lung and
and breast cancers 🤓🤓

A great review by the giants of the field to start 💯💯

☑️Summary of the available data
☑️A roadmap for further studies 💉💉
☑️Emphasizing the need for collaborations and biomarker-driven approaches 🔎🔎

💊Adjuvant Aspirin in Breast Cancer

The Alliance A011502 randomized phase 3 trial
JAMA

❌Negative study, lack of benefit for invasive DFS and OS

➡️3020 participants
➡️high-risk nonmetastatic breast cancer
➡️Aspirin vs placebo
➡️By median follow-up of 33.8 months,

📪When you see this in your mailbox, start getting ready to go to ASCO #ASCO24 ⭐️💫☄️

⭐️⭐️⭐️Excited to see all friends and experts⭐️⭐️⭐️

...and present our data about unclassified #renal #cell #cancer
🧬Applying genomic analysis to refine unclassified renal cell carcinoma.🧬

3️⃣2️⃣1️⃣⏰️🔝Counting down the days! Just one month left until #ASCO24 🌍

Team OncoAlert is geared up and ready to go! 🚨

🌟 Featuring global team:
Gil Morgan, MD 🇺🇸
Alizée Camps - - Maléa 🇫🇷
Marta Perachino 🇮🇹
Kathrin Heinrich 🇩🇪
Biagio Ricciuti, MD PhD 🇺🇸
Deniz Can Guven 🇹🇷
Emre Yekedüz

I am really happy to be one of the first authors of this article in JNM and have the oppurtunity to collect and analyse the data of patients received > 6 cycles of LuPSMA from different NM centers in Germany. Higlights:
🎯Favorable safety
🎯Maintained response

Really interesting article by Niklas Klümper in EJC 🤓🤓

Post-hoc analyses from the IMvigor211 and IMmotion151 💉💉

A simple and cheap predictor of IO efficacy >Blood sodium levels 🧂🧂

Could be very practical and beneficial for the patients 🤞🤞

A great discussion on the

Best way to stay updated in the #Oncotwitter 💯💯

Great weekly summaries by the Mr. OncoAlert himself 🤓🤓 Gil Morgan, MD

Happy to see some friends too 🇹🇷🇹🇷 Emre Yekedüz Erman Akkus

Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Marta Perachino Kathrin Heinrich Hidehito HORINOUCHI Dr. Iván R. González